These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18563509)

  • 1. Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.
    Eriksson BI; Friedman RJ; Cushner FD; Lassen MR
    Clin Orthop Relat Res; 2008 Aug; 466(8):2009-11; author reply 2012-4. PubMed ID: 18563509
    [No Abstract]   [Full Text] [Related]  

  • 2. Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.
    Sharrock NE; Gonzalez Della Valle A; Go G; Lyman S; Salvati EA
    Clin Orthop Relat Res; 2008 Mar; 466(3):714-21. PubMed ID: 18264861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
    Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty.
    Jameson SS; Rymaszewska M; Hui AC; James P; Serrano-Pedraza I; Muller SD
    J Bone Joint Surg Am; 2012 Sep; 94(17):1554-8. PubMed ID: 22832942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT).
    Rota E; Bazzan M; Fantino G
    Thromb Haemost; 2008 Apr; 99(4):779-81. PubMed ID: 18392338
    [No Abstract]   [Full Text] [Related]  

  • 6. Rivaroxaban to prevent pulmonary embolism after hip or knee replacement.
    Cios D; Fanikos J
    Circulation; 2012 Apr; 125(14):e542-4. PubMed ID: 22492951
    [No Abstract]   [Full Text] [Related]  

  • 7. Rivaroxaban (Xarelto)--a new oral anticoagulant.
    Med Lett Drugs Ther; 2011 Aug; 53(1371):65-7. PubMed ID: 21860366
    [No Abstract]   [Full Text] [Related]  

  • 8. [Thromboprophylaxis in hip and knee arthroplasty. Are the new anticoagulants better than those previously used?].
    Nielsen JD
    Ugeskr Laeger; 2005 May; 167(21):2261-5. PubMed ID: 15962850
    [No Abstract]   [Full Text] [Related]  

  • 9. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
    Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
    Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban versus enoxaparin after total knee arthroplasty.
    Gómez-Outes A; Suárez-Gea ML; Blázquez-Pérez A; Pozo-Hernández C; Vargas-Castrillón E
    Lancet; 2009 Aug; 374(9691):682; author reply 683. PubMed ID: 19716955
    [No Abstract]   [Full Text] [Related]  

  • 11. Fondaparinux: new preparation. No better than LMWH in preventing pulmonary embolism.
    Prescrire Int; 2003 Feb; 12(63):3-5. PubMed ID: 12602371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
    N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with ximelagatran in orthopaedic surgery.
    Eriksson B
    Drugs; 2004; 64 Suppl 1():27-35. PubMed ID: 15586625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
    Welzel D; Hull R; Fareed J
    Int Angiol; 2011 Jun; 30(3):199-211. PubMed ID: 21617603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
    N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ultimate anticoagulants?
    Cardiovasc J Afr; 2010; 21(1):55-6. PubMed ID: 20224850
    [No Abstract]   [Full Text] [Related]  

  • 17. Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.
    Prescrire Int; 2009 Aug; 18(102):151-3. PubMed ID: 19743567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban for thromboprophylaxis.
    Lotke PA
    N Engl J Med; 2008 Nov; 359(20):2174; author reply 2175-6. PubMed ID: 19009675
    [No Abstract]   [Full Text] [Related]  

  • 19. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
    Lu X; Lin J
    BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV; Quinlan DJ; Dahl OE; Schulman S
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.